Labcorp (NYSE:LH) Stock Gets Price Target Increase from Truist Financial

Labcorp (NYSE:LH) had its price target raised by research analysts at Truist Financial from $365.00 to $395.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. Truist Financial‘s price objective points to a potential upside of 9.03% from the company’s current price.

A number of other equities research analysts also recently weighed in on LH. Barclays set a $380.00 price target on shares of Labcorp and gave the company an “equal weight” rating in a report on Wednesday. UBS Group reissued a “buy” rating and set a $420.00 price objective on shares of Labcorp in a research note on Thursday. Piper Sandler boosted their target price on Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Robert W. Baird increased their price target on Labcorp from $361.00 to $396.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Bank of America lifted their target price on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $361.58.

Labcorp Price Performance

NYSE:LH traded up $2.04 during midday trading on Thursday, hitting $362.29. 233,562 shares of the stock were exchanged, compared to its average volume of 693,676. The company has a market capitalization of $29.38 billion, a price-to-earnings ratio of 29.96, a P/E/G ratio of 1.88 and a beta of 0.87. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. Labcorp has a one year low of $244.52 and a one year high of $371.00. The business has a 50-day moving average price of $321.91 and a two-hundred day moving average price of $286.47.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. The firm had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company posted $4.18 EPS. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. Sell-side analysts predict that Labcorp will post 18.32 EPS for the current year.

Insider Transactions at Labcorp

In related news, EVP Amy Summy sold 924 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total transaction of $283,427.76. Following the completion of the sale, the executive vice president directly owned 6,956 shares in the company, valued at approximately $2,133,683.44. This trade represents a 11.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Adam Schechter sold 4,669 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the transaction, the chief executive officer directly owned 102,565 shares in the company, valued at $32,858,749.05. The trade was a 4.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,593 shares of company stock valued at $2,733,295 over the last three months. 0.84% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Labcorp

Hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC lifted its stake in shares of Labcorp by 1.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock worth $607,241,000 after buying an additional 22,170 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Labcorp by 2.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,332,775 shares of the medical research company’s stock worth $355,569,000 after buying an additional 28,584 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Labcorp by 19.4% in the first quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock valued at $218,901,000 after acquiring an additional 133,549 shares during the period. Diamond Hill Capital Management LLC Investment Advisor bought a new stake in shares of Labcorp in the second quarter valued at approximately $168,222,000. Finally, Bessemer Group Inc. grew its stake in shares of Labcorp by 47.3% in the first quarter. Bessemer Group Inc. now owns 579,036 shares of the medical research company’s stock worth $154,493,000 after acquiring an additional 185,847 shares during the last quarter. 95.94% of the stock is owned by institutional investors and hedge funds.

Labcorp News Roundup

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Q3 results exceeded expectations. Labcorp reported adjusted earnings of $4.78 per share versus the $4.64 consensus estimate, while revenue rose 6.9% year over year to $3.81 billion, above the $3.76 billion forecast. Earnings also improved from $4.18 per share in the prior-year quarter. Labcorp Q3 earnings report
• Positive Sentiment: Management raised its 2026 outlook. Labcorp increased its full-year enterprise revenue-growth forecast to 5.9%-6.7% and adjusted EPS guidance to $18.30-$18.70, signaling continued confidence in demand and operating performance. Labcorp reports third-quarter results
• Positive Sentiment: Both operating segments grew. Diagnostics Laboratories revenue increased 6.5% to $2.95 billion, while Biopharma Laboratory Services revenue climbed 8.5% to $866.7 million. The company also cited margin expansion, four announced or completed transactions, and FDA approval for its PGDx elio tissue complete companion diagnostic for advanced melanoma. Labcorp Q3 outlook update
• Positive Sentiment: Analysts became more constructive. Robert W. Baird raised its price target from $361 to $396 and assigned an “outperform” rating, while Truist increased its target from $365 to $395 and maintained a “buy” rating. Truist raises Labcorp price target
• Neutral Sentiment: Labcorp expanded access to FDA-approved HPV screening tests through a partnership with Waters, potentially supporting longer-term diagnostics adoption. Waters and Labcorp HPV testing partnership
• Negative Sentiment: Recent insider-trading data showed only sales by Labcorp insiders over the past six months, with no reported open-market purchases. This may modestly temper sentiment, although the transactions do not change the stronger earnings-driven outlook.

About Labcorp

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.